copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Our tireless pursuit | Geron With a seasoned leadership team with world-class expertise spanning research, clinical development, regulatory, manufacturing and commercial experience in hematologic malignancies, Geron is prepared to deliver on our mission to change lives by changing the course of blood cancer
Careers | Geron Geron is always accepting applications for employment opportunities Click on the ‘ Explore Open Positions ’ link above to find all of the open positions for which we are currently recruiting
Geron Corporation - Investors Media Geron is a commercial-stage biopharmaceutical company with a first-in-class telomerase inhibitor that is approved in the United States for the treatment of certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia
Clinical trials exploring imetelstat | Geron Geron sponsored trials IMpactMF, our pivotal Phase 3 clinical trial in JAK inhibitor relapsed refractory MF, is an open label, 2:1 randomized, controlled clinical trial of imetelstat to evaluate a potential improvement in overall survival compared to best available therapy
Advancing how blood cancers are treated | Geron Scientific research has shown that telomerase activity is increased in malignant stem and progenitor cells in the bone marrow Inhibiting telomerase activity aims to potentially reduce proliferation and induce death of malignant cells Geron is exploring the broad potential of telomerase inhibition across multiple hematologic malignancies
Our story continues to evolve | Geron Geron is founded by Mike West, a pioneer in stem cell, cellular aging and telomerase research, and Alex Barkas, a venture capitalist who at the time was a partner at Kleiner Perkins Caufield Byers
Geron Corporation - Investors Media - Press Releases Geron Announces European Commission Approval of RYTELO® (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adults With Transfusion-Dependent Anemia Due to Lower-Risk MDS
Geron Corporation - Geron Announces FDA Approval of RYTELO™ (imetelstat . . . Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer Our first-in-class telomerase inhibitor RYTELO™ (imetelstat) is FDA-approved for the treatment of adult patients with lower-risk MDS with transfusion dependent anemia
Medicines - Geron Geron is a commercial stage biopharmaceutical company commercializing a first-in-class telomerase inhibitor for relapsed refractory myelodysplastic syndromes